Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenetic landscape of lymphomagenesis in coeliac disease.
Cording S, Lhermitte L, Malamut G, Berrabah S, Trinquand A, Guegan N, Villarese P, Kaltenbach S, Meresse B, Khater S, Dussiot M, Bras M, Cheminant M, Tesson B, Bole-Feysot C, Bruneau J, Molina TJ, Sibon D, Macintyre E, Hermine O, Cellier C, Asnafi V, Cerf-Bensussan N; CELAC network. Cording S, et al. Among authors: trinquand a. Gut. 2022 Mar;71(3):497-508. doi: 10.1136/gutjnl-2020-322935. Epub 2021 Feb 12. Gut. 2022. PMID: 33579790 Free PMC article.
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°. Cheminant M, et al. Among authors: trinquand a. Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17. Gut. 2019. PMID: 30448772
A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues.
Derrieux C, Trinquand A, Bruneau J, Verkarre V, Lhermitte L, Alcantara M, Villarese P, Meresse B, Sibon D, Hermine O, Brousse N, Molina T, Cellier C, Cerf-Bensussan N, Malamut G, Macintyre E. Derrieux C, et al. Among authors: trinquand a. J Mol Diagn. 2019 Jan;21(1):111-122. doi: 10.1016/j.jmoldx.2018.08.006. Epub 2018 Sep 28. J Mol Diagn. 2019. PMID: 30268943 Free article.
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.
Saillard C, Guermouche H, Derrieux C, Bruneau J, Frenzel L, Couronne L, Asnafi V, Macintyre E, Trinquand A, Lhermitte L, Molina T, Suarez F, Lemonnier F, Kosmider O, Delarue R, Hermine O, Cheminant M. Saillard C, et al. Among authors: trinquand a. Hematol Oncol. 2017 Dec;35(4):864-868. doi: 10.1002/hon.2319. Epub 2016 Jun 29. Hematol Oncol. 2017. PMID: 27353473
Oncogenic PTEN functions and models in T-cell malignancies.
Tesio M, Trinquand A, Macintyre E, Asnafi V. Tesio M, et al. Among authors: trinquand a. Oncogene. 2016 Jul 28;35(30):3887-96. doi: 10.1038/onc.2015.462. Epub 2015 Nov 30. Oncogene. 2016. PMID: 26616857 Review.
Targeting IRAK1 in T-cell acute lymphoblastic leukemia.
Dussiau C, Trinquand A, Lhermitte L, Latiri M, Simonin M, Cieslak A, Bedjaoui N, Villarèse P, Verhoeyen E, Dombret H, Ifrah N, Macintyre E, Asnafi V. Dussiau C, et al. Among authors: trinquand a. Oncotarget. 2015 Aug 7;6(22):18956-65. doi: 10.18632/oncotarget.4150. Oncotarget. 2015. PMID: 26068967 Free PMC article.
Loss of ARHGEF1 causes a human primary antibody deficiency.
Bouafia A, Lofek S, Bruneau J, Chentout L, Lamrini H, Trinquand A, Deau MC, Heurtier L, Meignin V, Picard C, Macintyre E, Alibeu O, Bras M, Molina TJ, Cavazzana M, André-Schmutz I, Durandy A, Fischer A, Oksenhendler E, Kracker S. Bouafia A, et al. Among authors: trinquand a. J Clin Invest. 2019 Mar 1;129(3):1047-1060. doi: 10.1172/JCI120572. Epub 2019 Feb 4. J Clin Invest. 2019. PMID: 30521495 Free PMC article.
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.
Pincez T, Bruneau J, Berteloot L, Piekarski E, Thomas C, Marçais A, Trinquand A, Castelle M, Garcelon N, Plantaz D, Cheminant M, Moshous D, Molina TJ, Hermine O, Macintyre E, Fischer A, Blanche S, Suarez F, Neven B. Pincez T, et al. Among authors: trinquand a. Haematologica. 2020 Sep 1;105(9):e461-464. doi: 10.3324/haematol.2019.230276. Haematologica. 2020. PMID: 33054064 Free PMC article. No abstract available.
Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia.
Trinquand A, Dos Santos NR, Tran Quang C, Rocchetti F, Zaniboni B, Belhocine M, Da Costa de Jesus C, Lhermitte L, Tesio M, Dussiot M, Cosset FL, Verhoeyen E, Pflumio F, Ifrah N, Dombret H, Spicuglia S, Chatenoud L, Gross DA, Hermine O, Macintyre E, Ghysdael J, Asnafi V. Trinquand A, et al. Cancer Discov. 2016 Sep;6(9):972-85. doi: 10.1158/2159-8290.CD-15-0675. Epub 2016 Jun 28. Cancer Discov. 2016. PMID: 27354269
36 results